

Chapter 231

Antiviral Drugs

Dirk M. Elston

REFERENCES

1. Celum C et al: Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. *N Engl J Med* **362**(5):427-439, 2010; [Epub Jan 20, 2010] [PMID: 20089951] [p1]
2. Vanpouille C, Lisco A, Margolis L: Acyclovir: A new use for an old drug. *Curr Opin Infect Dis* **22**(6):583-587, 2009
3. Vanpouille C et al: A new class of dual-targeted antivirals: monophosphorylated acyclovir pro-drug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. *J Infect Dis* **201**(4):635-643, 2010; [Epub Jan 19, 2010] [PMID: 20085496]
4. McMahon MA et al: Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs. *AIDS* **24**(2):319-323, 2010
5. Leung DT et al: Inadequacy of plasma acyclovir levels at delivery in patients with genital herpes receiving oral acyclovir suppressive therapy in late pregnancy. *J Obstet Gynaecol Can* **31**(12):1137-1143, 2009
6. Duan R et al: Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. *J Infect Dis* **200**(9):1402-1414, 2009
7. Kamel AO et al: Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time. *AAPS Pharm SciTech* **10**(4):1427-1436, 2009
8. Elshafeey AH, Kamel AO, Awad GA: Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. *Colloids Surf B Biointerfaces* **75**(2):398-404, 2010
9. Agut H et al: Testing the susceptibility of human herpesviruses to antivirals. *Future Microbiol* **4**:1111-1123, 2009
10. McMahon MA, Shen L, Siliciano RF: New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. *Curr Opin Infect Dis* **22**(6):574-582, 2009
11. Yadav M et al: Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography-tandem mass spectrometry method. *J Chromatogr B Analyt Technol Biomed Life Sci* **877**(8-9):680-688, 2009
12. Bonnar PE: Suppressive valacyclovir therapy to reduce genital herpes transmission: Good public health policy? *Mcgill J Med* **12**(1):39-46, 2009
13. Kim HN et al: Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. *Sex Transm Dis* **35**(2):124-128, 2008
14. Sperling RS et al: The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes. *Sex Transm Dis* **35**(3):286-290, 2008
15. Martens MG et al: Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes. *Infect Dis Obstet Gynecol* **2009**:105376, 2009
16. Miserocchi E et al: Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. *Am J Ophthalmol* **144**(4):547-551, 2007
17. Hull C et al: Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: A patient-initiated, double-blind, placebo-controlled pilot trial. *J Eur Acad Dermatol Venereol* **23**(3):263-267, 2009
18. Ozçay F et al: The role of valacyclovir on Epstein-Barr virus viral loads in pediatric
19. Hoshino Y et al: Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. *J Virol* **83**(22):11857-11861, 2009
20. Aoki FY: Contemporary antiviral drug regimens for the prevention and treatment of orolabial and anogenital herpes simplex virus infection in the normal host: four approved indications and 13 off-label uses. *Can J Infect Dis* **14**(1):17-27, 2003

21. Zeng L et al: Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. *Antimicrob Agents Chemother* **53**(7):2918-2927, 2009
22. Bomgaars L et al: Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. *Pediatr Blood Cancer* **51**(4):504-508, 2008
23. Kimberlin DW: Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. *Clin Infect Dis* **50**(2):221-228, 2010
24. Daito J et al: Symmetrical drug-related intertriginous and flexural exanthema caused by valacyclovir. *Dermatology* **218**(1):60-62, 2009
25. Ebo DG et al: Immediate allergy from valacyclovir. *Allergy* **63**(7):941-942, 2008
26. Asahi T et al: Valacyclovir neurotoxicity: clinical experience and review of the literature. *Eur J Neurol* **16**(4):457-460, 2009
27. Smith JP et al: Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after high-dose valacyclovir in subjects with normal and impaired renal function. *Antimicrob Agents Chemother* **54**(3):1146-51, 2010; [Epub Dec 28, 2009] [PMID: 20038622]
28. Hasler-Nguyen N et al: Evaluation of the in vitro skin permeation of antiviral drugs from penciclovir 1% cream and acyclovir 5% cream used to treat herpes simplex virus infection. *BMC Dermatol* **9**:3, 2009
29. Zhu W et al: Microemulsion-based hydrogel formulation of penciclovir for topical delivery. *Int J Pharm* **378**(1-2):152-158, 2009
30. Lv Q et al: Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. *Int J Pharm* **372**(1-2):191-198, 2009
31. Zhu W et al: Formulation design of microemulsion for dermal delivery of penciclovir. *Int J Pharm* **360**(1-2):184-90, 2008
32. Harpaz R et al: Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* **57**(RR-5):1-30, 2008
33. Bodsworth N et al: 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study. *Sex Health* **5**(3):219-225, 2008
34. Abudalu M et al: Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. *Clin Infect Dis* **47**(5):651-658, 2008
35. Aoki FY: The continuing evolution of antiviral therapy for recurrent genital herpes: 1-day patient-initiated treatment with famciclovir. *Herpes* **14**(3):62-65, 2007
36. Bartlett BL et al: Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial. *J Clin Virol* **43**(2):190-195, 2008
37. Ogungbenro K et al: Population pharmacokinetics and optimal design of paediatric studies for famciclovir. *Br J Clin Pharmacol* **68**(4):546-560, 2009
38. Sáez-Llorens X et al: Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. *Antimicrob Agents Chemother* **53**(5):1912-1920, 2009
39. Leone P et al: One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients. *Curr Med Res Opin* **26**(3):653-661, 2010; [Epub Jan 13, 2010] [PMID: 20070143]
40. Htwe TH, Bergman S, Koirala J: Famciclovir substitution for patients with acyclovir-associated renal toxicity. *J Infect* **57**(3):266-268, 2008
41. Te CC, Le V, Allee M: Famciclovir-induced leukocytoclastic vasculitis. *Ann Pharmacother* **42**(9):1323-1326, 2008
42. Wilhelmus KR: Therapeutic interventions for herpes simplex virus epithelial keratitis. *Cochrane Database Syst Rev* (1):CD002898, 2008
43. Kaufman HE et al: Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection. *J Ocul Pharmacol Ther* **24**(1):34-42, 2008
44. Guess S, Stone DU, Chodosh J: Evidence-based treatment of herpes simplex virus keratitis: A systematic review. *Ocul Surf* **5**(3):240-250, 2007
45. Perrottet N et al: Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. *BMC Infect Dis* **10**(1):2, 2010
46. Perrottet N et al: Valganciclovir in adult solid organ transplant recipients: Pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. *Clin Pharmacokinet* **48**(6):399-418, 2009

47. Isegawa Y et al: PCR with quenching probes enables the rapid detection and identification of ganciclovir-resistance-causing U69 gene mutations in human herpesvirus 6. *Mol Cell Probes* 24(4):167-177, 2010; [Epub Jan 15, 2010]
48. Marshall BC, Koch WC: Antivirals for cytomegalovirus infection in neonates and infants: Focus on pharmacokinetics, formulations, dosing, and adverse events. *Paediatr Drugs* 11(5):309-321, 2009
49. Duan R et al: Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. *J Infect Dis* 198(5):659-663, 2008
50. Hatchette T et al: Foscarnet salvage therapy for acyclovir-resistant varicella zoster: Report of a novel thymidine kinase mutation and review of the literature. *Pediatr Infect Dis J* 27(1):75-77, 2008
51. Wang H et al: Low-dose foscarnet preemptive therapy for cytomegalovirus viremia after haploidentical bone marrow transplantation. *Biol Blood Marrow Transplant* 15(4):519-520, 2009
52. Charpentier C et al: Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients. *J Clin Virol* 43(2):212-215, 2008
53. Rodriguez J et al: Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection. *Liver Transpl* 13(10):1396-1400, 2007
54. Michaelis M et al: Valproic acid interferes with antiviral treatment in human cytomegalovirus-infected endothelial cells. *Cardiovasc Res* 77(3):544-550, 2008
55. De Clercq E: Emerging antiviral drugs. *Expert Opin Emerg Drugs* 13(3):393-416, 2008
56. Jesus DM et al: Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus. *J Virol* 83(22):11477-11490, 2009
57. Sonvico F et al: Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections. *AAPS J* 11(2):242-249, 2009
58. Van Pachterbeke C et al: Topical treatment of CIN 2+ by cidofovir: Results of a phase II, double-blind, prospective, placebo-controlled study. *Gynecol Oncol* 115(1):69-74, 2009
59. Coremans G, Snoeck R: Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions. *Expert Opin Pharmacother* 10(8):1343-1352, 2009
60. Calista D: Topical 1% cidofovir for the treatment of vulvar intraepidermal neoplasia (VIN1) developed on lichen sclerosus. *Int J Dermatol* 48(5):535-536, 2009
61. Amine A et al: Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. *PLoS One* 4(3):e5018, 2009
62. Field S, Irvine AD, Kirby B: The treatment of viral warts with topical cidofovir 1%: our experience of seven paediatric patients. *Br J Dermatol* 160(1):223-224, 2009
63. De Socio GV et al: Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma. *Int J STD AIDS* 19(10):715-716, 2008
64. Cusack C et al: Successful treatment of florid cutaneous warts with intravenous cidofovir in an 11-year-old girl. *Pediatr Dermatol* 25(3):387-389, 2008
65. Wei H et al: Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. *J Virol* 83(2):1115-1125, 2009
66. Bhadri VA, Lee-Horn L, Shaw PJ: Safety and tolerability of cidofovir in high-risk pediatric patients. *Transpl Infect Dis* 11(4):373-379, 2009
67. Tchernev G: Sexually transmitted papillomavirus infections: Epidemiology pathogenesis, clinic, morphology, important differential diagnostic aspects, current diagnostic and treatment options. *An Bras Dermatol* 84(4):377-389, 2009
68. Lott DG, Krakovitz PR: Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis. *Laryngoscope* 119(3):567-570, 2009
69. Donne AJ et al: Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease. *Antivir Ther* 14(7):939-952, 2009
70. Donne AJ et al: Cidofovir induces an increase in levels of low-risk and high-risk HPV E6. *Head Neck* 31(7):893-901, 2009
71. Dvorak CC et al: Development of herpes simplex virus stomatitis during receipt of cidofovir therapy. *Clin Infect Dis* 49(8):e92-e95, 2009
72. Piccolo P et al: A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. *Antivir Ther* 14(8):1165-1174, 2009

73. Jones J et al: Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: An updated systematic review and economic evaluation. *Health Technol Assess* 13(35):1-172, 2009
74. Scott LJ, Keating GM: Entecavir: a review of its use in chronic hepatitis B. *Drugs* 69(8):1003-1033, 2009
75. Duong A, Mousa SA: Current status of nucleoside antivirals in chronic hepatitis B. *Drugs Today (Barc)* 45(10):751-761, 2009
76. McMahon MA, Shen L, Siliciano RF: New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. *Curr Opin Infect Dis* 22(6):574-582, 2009
77. Gurusamy KS et al: Antiviral therapy for recurrent liver graft infection with hepatitis C virus. *Cochrane Database Syst Rev* (1):CD006803, 2010
78. Enomoto N, Maekawa S: HCV genetic elements determining the early response to peginterferon and ribavirin therapy. *Intervirology* 53(1):66-69, 2010
79. Iorio A et al: Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. *Cochrane Database Syst Rev* (1):CD004888, 2010
80. Brok J, Gluud LL, Gluud C: Ribavirin plus interferon versus interferon for chronic hepatitis C. *Cochrane Database Syst Rev* (1):CD005445, 2010
81. Farshidi D, Chiu MW: Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C. *J Am Acad Dermatol* 62(1):164-165, 2010
82. Mistry N, Shapero J, Crawford RI: A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. *Can J Gastroenterol* 23(10):677-683, 2009
83. Sato M, Sueki H, Iijima M: Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-alpha-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. *Clin Exp Dermatol* 34(8):e814-e817, 2009
84. Abbott IJ et al: Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report. *J Med Case Reports* 10;3:7289, 2009
85. Shuja F et al: Interferon induced sarcoidosis with cutaneous involvement along lines of venous drainage in a former intravenous drug user. *Dermatol Online J* 15(12):4, 2009
86. Centers for Disease Control and Prevention—Federal Government Agency [US], Department of Health and Human Services (US)—Federal Government Agency [US]. 1998 Dec 1 (updated 2008 Nov 3), 139 pages, (NGC:006760)
87. Primary care guidelines for the management of persons infected with human immunodeficiency virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Infectious Diseases Society of America—Medical Specialty Society, 2004, Sep 1, 21 pages, (NGC:003793)
88. Phillips EJ, Mallal SA: HLA and drug-induced toxicity. *Curr Opin Mol Ther* 11(3):231-242, 2009
89. Rodriguez-Nóvoa S, Soriano V: Current trends in screening across ethnicities for hypersensitivity to abacavir. *Pharmacogenomics* 9(10):1531-1541, 2008
90. Eron JJ Jr.: Antiretroviral therapy: new drugs, formulations, ideas, and strategies. *Top HIV Med* 17(5):146-150, 2009
91. Minzi OM, Irunde H, Moshiro C: HIV patients presenting common adverse drug events caused by highly active antiretroviral therapy in Tanzania. *Tanzan J Health Res* 11(1):5-10, 2009
92. Atzori L et al: Bullous skin eruption in an HIV patient during antiretroviral drugs therapy. *Dermatol Ther* 21(Suppl. 2):S30-S34, 2008
93. Johnson LB, Saravolatz LD: Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. *Clin Infect Dis* 48(8):1123-1128, 2009
94. Fulco PP, McNicholl IR: Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. *Pharmacotherapy* 29(3):281-294, 2009
95. Maggiolo F, Efavirenz: a decade of clinical experience in the treatment of HIV. *J Antimicrob Chemother* 64(5):910-928, 2009
96. Vemula S et al: Incidence and risk factors for non-nucleoside reverse transcriptase inhibitors (NNRTI)-related rash in Thai children with HIV infection. *J Med Assoc Thai* 90(11):2437-2441, 2007
97. Hall DB, Macgregor TR: Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites. *HIV Clin Trials* 8(6):391-399, 2007
98. Manosuthi W et al: Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL. *Int J STD AIDS* 18(11):782-786, 2007

99. Moura MD et al: Oral adverse effects due to the use of Nevirapine. *J Contemp Dent Pract* 9(1):84-90, 2008
100. Meyssonier V, Costagliola D, Caumes PE: Nevirapine-associated toxicity in Niger. *HIV Med* 9(1):62-63, 2008
101. Chen J et al: Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. *Chem Res Toxicol* 21(9):1862-1870, 2008
102. Fulco PP, McNicholl IR: Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. *Pharmacotherapy* 29(3):281-294, 2009
103. Mercier S et al: Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: A case-control study. *J Acquir Immune Defic Syndr* 51(2):224-230, 2009
104. Sarni RO et al: Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed. *J Pediatr (Rio J)* 85(4):329-334, 2009
105. Goulbourne CN, Vaux DJ: HIV protease inhibitors inhibit FACE1/ZMPSTE24: A mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy? *Biochem Soc Trans* 38(Pt 1):292—296, 2010
106. Benedini S et al: Effect of L-acetylcarnitine on body composition in HIV-related lipodystrophy. *Horm Metab Res* 41(11):840-845, 2009
107. McKinnell JA, Saag MS: Novel drug classes: Entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists]. *Curr Opin HIV AIDS* 4(6):513-517, 2009
108. Bogoch I, Walmsley S: First-line regimen failure of antiretroviral therapy: A clinical and evidence-based approach. *Curr Opin HIV AIDS* 4(6):493-498, 2009

